Zetuvit® Plus Silicone Border
![](/-/media/corporate-news/press-release/key-financial-figures-2020/zetuvit-plus-silicone-border.jpg?h=486&iar=0&mw=324&w=324&rev=551824850d1547d0aff27cf91c471b68&sc_lang=en&hash=8E4D9972E865D4B188F2729F80011256)
Sales & organic sales growth | |
Group | EUR 2.433 billion (+14.6%) |
Wound Management | EUR 452.1 million (-4.5%) |
Infection Management | EUR 829.8 million (+60.9%) |
Incontinence Management | EUR 690.5 million (-0.2%) |
Other Group Activities | EUR 460.6 million (+4.5%) |
"The pandemic resulted in positive special effects on sales and earnings. That, however, cannot hide the fact that Covid-19 will pose major challenges for all healthcare market participants, including us."
Despite the challenges of the pandemic, the projects of our transformation program advanced according to plan. These projects include the development of innovative products, cost improvements, e.g. through automation in production and logistics, the development of digital business models as well as new offerings for the outpatient sector.
“In 2020, HARTMANN reached the planned milestones of our transformation program. In parallel with the coronavirus pandemic, this was only possible with the dedicated cooperation of all employees. Thanks to their commitment, our company is well on its way to implementing its strategy,” says Britta Fünfstück.
HARTMANN lived up to its responsibility as an essential supplier to the sector. The company secured the expansion of its production and logistics during the crisis and protected the health of its employees through immediate preventive measures.
“HARTMANN has succeeded in ensuring the deliverability of selected product groups despite strongly increased demand and while maintaining all quality standards. Our strong teamwork and innovative spirit made these excellent results possible. We can all be proud of this,” says Britta Fünfstück.
On one hand, the less pronounced positive effects from the pandemic in 2021 are to be expected; on the other hand, negative effects and increasing budget pressure in healthcare systems will increase significantly. The investment requirements for implementing the transformation program must be taken into consideration, as well. HARTMANN therefore expects a moderate decline in organic sales and adjusted EBITDA of EUR 210 million to EUR 260 million. There is a high degree of forecast uncertainty for 2021 as the further development of the pandemic remains unclear.
“The positive impact of the pandemic in fiscal year 2020 will only materialize this year to a small degree. Large parts of our markets are experiencing a decline in demand. We also anticipate that the increasing budget pressure will accelerate and burden all market participants in the healthcare sector. 2021 will be a challenging year for the Press Release HARTMANN GROUP and the entire industry. Therefore, it is crucial for us to continue to consistently implement our transformation program in 2021,” Britta Fünfstück emphasizes.
The Annual Report and Consolidated Financial Statements for the 2020 financial year can be found at www.corporate.hartmann.info/en/investor-relations.
The HARTMANN GROUP is one of the leading European providers of professional medical and care products and associated services. Every day, healthcare professionals and patients rely on HARTMANN brands in the segments of Incontinence Management (e.g. MoliCare®), Wound Care (e.g. Zetuvit®, Cosmopor®) and Infection Management (e. g. Sterillium®). This is expressed in our brand promise of “Helps. Cares. Protects.” HARTMANN generated sales of EUR 2.3 billion in the 2023 financial year. Founded in 1818, the Company sells its products and solutions in 130 countries around the world. For the future, the HARTMANN GROUP is currently implementing its strategic Transformation Program with its high-performance, customer-oriented and passionate team.
To learn more about the HARTMANN GROUP, visit www.corporate.hartmann.info.